Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secured access to vemurafenib for patients with tumors harboring BRAF genomic alterations
2014-001225-33Phase 2Active
- Sponsor
- Unicancer
- Start
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vemurafenib in hairy cell leukemia (HCL) and cancer, sponsored by Unicancer. Primary endpoint: Objective response. Started Jul 2014; status: active.
02
Drugs
vemurafenib
03
Conditions
hairy cell leukemia (HCL)cancer
Beyond the preview
Go deeper on 2014-001225-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001225-33.